Northwire Canada EditionFriday, November 6, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,113.50 +1.0% Silver 52.38 +0.2% Copper 6.21 −3.4% Oil 90.52 +2.7% Palladium 1,034.00 +3.1% GRZ 5.25 −8.7% TNGD 5.20 +2.0% IMG 24.46 −0.1% III 6.05 −2.6% SCMI 0.900 −5.3% TSK 0.810 −1.2% MEK 0.040 +0.0% GAU 2.99 +2.0% SVM 11.69 −3.5% NGEX 20.70 −4.6% WPM 185.96 +1.2% ETG 2.58 −7.9% CG 29.87 −0.2% EMO 0.190 −2.6% TUF 0.660 −5.7% APMI 0.095 −13.6% Gold 4,113.50 +1.0% Silver 52.38 +0.2% Copper 6.21 −3.4% Oil 90.52 +2.7% Palladium 1,034.00 +3.1% GRZ 5.25 −8.7% TNGD 5.20 +2.0% IMG 24.46 −0.1% III 6.05 −2.6% SCMI 0.900 −5.3% TSK 0.810 −1.2% MEK 0.040 +0.0% GAU 2.99 +2.0% SVM 11.69 −3.5% NGEX 20.70 −4.6% WPM 185.96 +1.2% ETG 2.58 −7.9% CG 29.87 −0.2% EMO 0.190 −2.6% TUF 0.660 −5.7% APMI 0.095 −13.6%
Financings

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

By The Northwire Desk — AI Analysis Mar 12, 2026 · 15:28 RKV · 0.13 Rakovina Therapeutics Inc.
RKV · Price

Executive Summary

  • The TSX Venture Exchange granted Rakovina Therapeutics a 30‑day extension to close its non‑brokered private placement, now expected to complete on or before April 9, 2026.
  • The offering seeks to raise up to $1,000,000 by selling 8,333,334 common shares at $0.12 per share.
  • Net proceeds will be used for near‑term working capital and strategic initiatives while the company evaluates longer‑term financing options.

Key Details

  • Extension Granted: 30‑day extension; new anticipated closing date ≤ April 9, 2026 (or other acceptable dates).
  • Offering Size: Up to 8,333,334 common shares.
  • Price per Share: $0.12.
  • Gross Proceeds Target: Approximately $1.0 million.
  • Finder’s Fee: Company may pay a finder’s fee to eligible finders who introduce subscribers.
  • Use of Net Proceeds:
  • Provide near‑term working capital.
  • Support ongoing corporate activities and strategic initiatives.
  • Continue evaluation of longer‑term financing alternatives.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from Rakovina Therapeutics Inc.

Jun 01, 2026 · 17:00

Rakovina Cuts Costs and Restructures Debt, But Pre-Revenue Burn Rate Demands Immediate Capital Infusion

Earnings Apr 30, 2026 · 17:10

Rakovina Therapeutics Confirms Accelerating Burn Rate and Critical Cash Position Despite Financing

Earnings Apr 22, 2026 · 04:00

AI-Driven Oncology Pipeline Validates Preclinical Efficacy

Other Mar 23, 2026 · 04:00

Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

Other Mar 05, 2026 · 20:50

Rakovina closes $1-million debenture unit financing

Financings Mar 05, 2026 · 20:06

Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

Financings